Fig. 4
Effect of vistusertib alone or in combination with fulvestrant on tumour progression in HBCx34 OvaR PDX models. a Long-term study assessing changes in tumour volume over 64 days of treatment in HBCx34 OvaR. HBCx34 OvaR is an ER+ PDX model which is resistant to E-deprivation and tamoxifen but sensitive to the anti-proliferative effects of fulvestrant. Mice were treated with vehicle control, fulvestrant, vistusertib or the combination, and data shows median tumour volume (mm3). Bars represent the percentage of volume change at the end of treatment compared with baseline, for each individual animal. b Venn diagram showing the intersect of genes up- and downregulated for the different treatments by RNA-seq analysis; tumours of three animals by group were evaluated. c Effect of vistusertib (n = 10), fulvestrant (n = 8) or the combination (n = 3) in relation to vehicle (n = 9) upon relative RNA expression of ERGs and RTKs by RT-qPCR. Error bars represent means ± SEM. Statistical analysis was performed using ANOVA with Dunnett’s multiple comparisons test. #Tendency to difference between groups by t test. Vist vistusertib, Fulv fulvestrant, Vist + Fulv combination treatment